Substance Use Disorder

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Cannabis diagnosis was the most prevalent substance use disorder across all age, sex, racial/ethnic, and treatment setting groups among youth psychiatric patients, accounting for more than 80% of all

Effect: decline; Cannabis SUD 10.4% of all patients; >80% of all SUD cases; 21.2% among ages 13-17

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21

Among youth psychiatric patients with a substance use disorder, younger age at first treatment (2-12 vs 13-17), female sex, and black race were each independently associated with substantially higher

Effect: decline; AOR 3.50 for ages 2-12 vs 13-17; AOR 2.48 for female vs male; AOR 3.26 for black vs white; CI: 95% CI 2.11-5.80 (ages 2-12); 95% CI 1.92-3.21